MWNA
XFOR icon

Marshall Wace North America’s X4 Pharmaceuticals XFOR Stock Holding History

Marshall Wace North America’s Portfolio XFOR Stock Details XFOR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q3 		$139K Buy
+875
New +$144K ﹤0.01% 1348
2020
Q2 		– Sell
-63
Closed -$19K – 1528
2020
Q1 		$19K Buy
+63
New +$17.9K ﹤0.01% 1139

Other funds holding XFOR

IC
Ikarian Capital Dallas, Texas $928M AUM 596.14% 1-Year Est. Return
BCLSI
Bain Capital Life Sciences Investors Boston, Massachusetts $1.68B AUM 126.09% 1-Year Est. Return
ACM
AIGH Capital Management Baltimore, Maryland $1.59B AUM 855.46% 1-Year Est. Return
O
OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.91B AUM 304.52% 1-Year Est. Return
ACM
Altium Capital Management New York $47.5M AUM 115.72% 1-Year Est. Return
SCM
Sio Capital Management New York $604M AUM 96.57% 1-Year Est. Return
Axa
Axa Paris, France $91.9M AUM 27.41% 1-Year Est. Return
MIM
Monashee Investment Management Boston, Massachusetts $59.6M AUM 181.61% 1-Year Est. Return

Marshall Wace North America's XFOR Position: Q3 2021 in Review

Marshall Wace North America opened a new position in X4 Pharmaceuticals (XFOR) in Q3 2021: 875 shares worth $139K. The stake represents ﹤0.01% of the portfolio and ranks #1348 among its holdings. This is a return to the name: Marshall Wace North America previously reported a position in XFOR as recently as Q1 2020.

Marshall Wace North America first reported a position in XFOR in Q1 2020 and has held it in 2 quarters since. 51 funds tracked by Wall St. Rank hold XFOR as of Q3 2021.

  • Marshall Wace North America held 875 shares of X4 Pharmaceuticals worth $139K as of Q3 2021.
  • X4 Pharmaceuticals was a new Marshall Wace North America position in Q3 2021.
  • X4 Pharmaceuticals made up ﹤0.01% of Marshall Wace North America's portfolio in Q3 2021, its #1348 holding.
  • Marshall Wace North America first reported a position in X4 Pharmaceuticals in Q1 2020 and has held it in 2 quarters since.
  • 51 funds tracked by Wall St. Rank held X4 Pharmaceuticals as of Q3 2021.

Based on Marshall Wace North America's 13F filing for Q3 2021, filed 15 Nov 2021.